文献速递头颈与中枢神经肿瘤骨软组织肉瘤与黑色素瘤

立体定向放射外科联合抗PD1治疗黑色素瘤脑转移的安全性与疗效回顾性研究

Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy.
PubMed 文献 · Eur J Cancer · 2020-06-11

该单中心回顾性研究纳入50例接受抗PD1联合立体定向放射外科(SRS)作为唯一放疗方式的黑色素瘤脑转移患者,中位随访38.89个月,中位总生存16.62个月,中位脑进展无生存13.2个月,未发现非预期毒性。

要点

  • 抗PD1联合SRS未出现非预期毒性,安全性可接受。
  • 中位总生存16.62个月,1、2、3年生存率分别为60%、40%、35%。
  • 中位脑进展无生存13.2个月,1、2、3年率分别为62.1%、49.7%、49.7%。

核心结论

  • 真实世界队列显示 upfront SRS 联合抗PD1 治疗黑色素瘤脑转移获得显著生存率且未揭示非预期毒性。

研究设计与样本

  • 单中心回顾性分析纳入50例接受抗PD1联合SRS作为唯一放疗方式(全程未行全脑放疗)的黑色素瘤脑转移患者。
  • 纳入SRS时正在使用抗PD1或SRS后最长3个月内开始抗PD1且治疗至少1年前的患者。

主要发现

  • 50例患者中,SRS靶向1个、2-3个和>3个脑转移灶的患者分别为17、16和17例。
  • 2例患者在首次评估前死亡;9例出现瘤周水肿增加,3例出现颅内出血,1例同时出现水肿和出血。
  • 中位随访38.89个月(四分位距24.43;45.28)。
  • 自SRS起中位总生存16.62个月,1年、2年、3年生存率分别为60%、40%、35%。
  • 中位脑进展无生存13.2个月,1年、2年、3年率分别为62.1%、49.7%、49.7%。

临床怎么用

  • 对于黑色素瘤脑转移患者,可考虑立体定向放射外科联合抗PD1治疗,需注意监测瘤周水肿和颅内出血。

局限性

  • 回顾性单中心设计,样本量50例,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Brain metastases can be effectively treated with stereotactic radiosurgery (SRS). Immune checkpoint inhibitors are now pivotal in metastatic melanoma care, but some concerns have emerged regarding the safety of their combination with radiation therapy. METHODS: We present a retrospective analysis of a cohort of patients treated by anti-PD1 and SRS as a sole modality of radiation therapy (no whole brain radiation therapy at any time) in a single institution. We included patients on anti-PD1 at the time of SRS or patients who started anti-PD1 within a maximum period of 3 months following SRS and were treated at least one year before the analysis. Clinical and serial imaging data were reviewed to determine the efficacy and the rate of adverse radiation effectss of the combination. RESULTS: A total of 50 patients were included. SRS targeted 1, 2 to 3 and >3 brain metastases in 17, 16 and 17 patients, respectively. Two patients died before the first evaluation. Nine patients presented with an increase in peritumoral oedema, three with intracranial haemorrhage and one patient with both oedema and haemorrhage. Median follow-up was 38.89 months (interquartile range 24.43; 45.28). Median overall survival from SRS was 16.62 months with 1-, 2- and 3-year rates of 60%, 40% and 35%, respectively. Median brain-Progression Free Survival was 13.2 months with 1, 2 and 3-year rates of 62.1%, 49.7% and 49.7%, respectively. CONCLUSIONS: This real-world cohort of patients treated with a homogeneous strategy combining upfront stereotactic radiosurgery and anti-PD1 shows remarkable survival rates and does not reveal unexpected toxicity.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Carron R, Gaudy-Marqueste C, Amatore F, et al. Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy. Eur J Cancer. 2020. PMID: 32535348. doi:10.1016/j.ejca.2020.04.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。